HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Dexibuprofen

HCID 39912
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
51146-56-6
Standard SMILES
CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
InChIKey
HEFNNWSXXWATRW-JTQLQIEISA-N
Molecular formula
C13H18O2
Average molar mass
206.28 g/mol
Monoisotopic mass
206.13067981

Overview

Dexibuprofen is an ibuprofen. It has a role as a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is an enantiomer of a levibuprofen.

Names & identifiers

Preferred name
Dexibuprofen
IUPAC
(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
English name
(S)-(+)-Ibuprofen
Molecular formula
C13H18O2
Molecular weight
206.28

Names & synonyms

DEXIBUPROFEN51146-56-6DexibuprofeneDexibuprofenoSeractild-IbuprotenDexibuprofenum(+)-(S)-p-Isobutylhydratropic acid(+)-Ibuprofen(2S)-2-(4-isobutylphenyl)propanoic acids-ibuprofen(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
Show more names
(S)-IBUPROFEN(S)-2-(4-Isobutylphenyl)propanoic acidRamelteon-7d-IbuprofenexibuprofenDeibuprofenDextroprofen
DTXSID9048724NSC-759814671DKG7P5S(S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acidDTXCID6028650CHEBI:43415Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, (S)-(2S)-2-(4-(2-methylpropyl)phenyl)propanoic acid

Database identifiers

CAS
51146-56-6
PubChem CID
39912
DTXSID
DTXSID9048724
ChEMBL
CHEMBL175
ChEBI
CHEBI:43415
UNII
671DKG7P5S
EC Number
610-620-9

Properties

Computed structural properties

XLogP
3.5
Topological polar surface area
37.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
4
Heavy atoms
15
Formal charge
0
Complexity
203

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

SolubilityInsoluble
Melting Point49-53

Physicochemical properties

Melting point
49 · 49-53 °C(lit.)
alpha
57 · 57 º (c=2, EtOH)
Boiling point
285.14 °C · 285.14°C (rough estimate)
Density
1.0364 · 1.0364 (rough estimate)
refractive index
59 ° · 59 ° (C=2, EtOH)
Flash point
230 °F · >230 °F
storage temp.
Sealed in dry,Room Temperature
solubility
45 % · 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 1.5 mg/mL
form
solid

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (85.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (85.7%)

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
hs_code
2916399090
risk_code
63-22
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xn
safety_code
45-36/37
Storage Class
11 - Combustible Solids
Hazard statements
H315-H319
Precautionary statements
P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313

Chemistry & industry

Pharmacology

ATC Code · 2 items

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingFor more information, refer to [ibuprofen].
PharmacodynamicsFor more information, refer to [ibuprofen].
Mechanism of Action · 1 item

Like common NSAIDs, dexibuprofen is an active enantiomer of [ibuprofen] that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX. For more information, refer to [ibuprofen].

Biological Half-LifeOral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours. For more information, refer to [ibuprofen].
Metabolism/Metabolites · 2 items

For more information, refer to [ibuprofen].

(S)-(+)-ibuprofen has known human metabolites that include 2-Hydroxyibuprofen and 3-Hydroxyibuprofen.

Absorption, Distribution and Excretion · 4 items

The time it take to reach peak plasma concentration is 2.25-5 hours post-administration of oral tablets containing 300mg of dexibuprofen. For more information, refer to [ibuprofen].

Mainly renal excretion. For more information, refer to [ibuprofen].

For more information, refer to [ibuprofen].

For more information, refer to [ibuprofen].

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >25000
Applications · 6 items

Related reactions

15 records
New reaction record
HRID 220715 reaction equation
HRID 220715As reactant
HRID 356841 reaction equation
HRID 356841As reactant
HRID 391197 reaction equation
HRID 391197As reactant
HRID 511942 reaction equation
HRID 511942As reactant
HRID 864689 reaction equation
HRID 864689As product
HRID 1467862 reaction equation
HRID 1467862As reactant
HRID 1589944 reaction equation
HRID 1589944As reactant
HRID 1609246 reaction equation
HRID 1609246As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Nikkaji
J384.813B
pka
4.41 · 4.41±0.10(Predicted)
color
white
optical activity
20 · [α]20/D +59°, c = 2 in ethanol
Water Solubility
insoluble
BRN
3590022 · 3590022
Stability
Stable. Incompatible with strong oxidizing agents.
InChI
1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
InChIKey
HEFNNWSXXWATRW-JTQLQIEISA-N
SMILES
CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O
CAS DataBase Reference
51146 · 51146-56-6(CAS DataBase Reference)
FDA UNII
671 DKG7P5S · 671DKG7P5S
ATC code
1 AE14 · M01AE14
Comptox DTXSID
9048724 · DTXSID9048724
UNSPSC Code
12352002 · 12352002
NACRES
22 · NA.22
Protein binding
99 % · >99%
Excreted unchanged in urine
82 · 82 (mainly as inactive metabolites)
Volume of distribution
10 · 10-11 Litres
Biological half-life
1.6 · 1.6-1.9 / Unchanged
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313
PPE
95 · Eyeshields, Gloves, type N95 (US)
Hazard Codes
Xn
Risk Statements
63 · 63-22
Safety Statements
45 · 45-36/37
WGK Germany
3 · 3
HS Code
2916399090 · 2916399090
Storage Class
11 · 11 - Combustible Solids

DescriptionDexibuprofen, the S-(+)-isomer of the widely used NSAID agent ibuprofen, was launched in Austria for the treatment of rheumatoid arthritis. While the racemic compound is commonly used clinically, the antiinflammatory activity is mediated via the S-isomer by inhibition of prostaglandin synthesis. It has also been demonstrated that the R-isomer is converted to the Santipode in vivo via a CoA thioester intermediate. Since CoA plays a pivotal role in intermediary metabolism and maintenance of the [acyl-CoA], generation of R-ibuprofen-CoA competitively inhibits many CoA-dependent reactions, which consequently produces perturbations of hepatocyte Intermediary metabolism and mitocondrial function. Pure S-ibuprofen usage, therefore, is preferred allowing a reduction in dosage level and an improved side effect profile.

DescriptionIbuprofen is a non-steroidal anti-inflammatory drug with diverse biochemical actions, most notably inhibiting COX-1 and COX-2 (IC50s = 2.6 and 1.53, μM, respectively). It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form. (S)-Ibuprofen also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50s = 62 and 122 μM, respectively). However, the enantiomers are equipotent in blocking superoxide formation, β-glucuronidase release, and LTB4 generation by stimulated neutrophils (IC50 values range from 0.14 to 0.58 μM). A majority of (R)-ibuprofen can be inverted to (S)-ibuprofen in humans after oral administration.

UsesA nonsteroidal anti-inflammatory drug (NSAID); activity resides primarily in the (S)-isomer

Usessedative

UsesIbuprofen is a non-steroidal anti-inflammatory drug with diverse biochemical actions, most notably inhibiting COX-1 and COX-2 (IC50s = 2.6 and 1.53, μM, respectively). It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form. (S)-Ibuprofen also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50s = 62 and 122 μM, respectively). However, the enantiomers are equipotent in blocking superoxide formation, β-glucuronidase release, and LTB4 generation by stimulated neutrophils (IC50 values range from 0.14 to 0.58 μM). A majority of (R)-ibuprofen can be inverted to (S)-ibuprofen in humans after oral administration.

General Description(S)-(+)-Ibuprofen is the enantiomer associated with the anti-inflammatory action of ibuprofen, which is widely used as a nonsteroidal anti-inflammatory drug in racemic form.

Upstream & downstream products

Upstream raw materials

1-Deoxy-1-(octylamino)-D-glucitol(R)-(+)-4-Isopropyl-2-oxazolidinone

Additional notes

DefinitionChEBI: Dexibuprofen is an ibuprofen. It has a role as a non-narcotic analgesic and a non-steroidal anti-inflammatory drug. It is an enantiomer of a levibuprofen.